

# Vijay Harypursat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1160184/publications.pdf>

Version: 2024-02-01

25  
papers

303  
citations

1307366

7  
h-index

940416

16  
g-index

29  
all docs

29  
docs citations

29  
times ranked

698  
citing authors

#	ARTICLE	IF	CITATIONS
1	No Statistically Apparent Difference in Antifungal Effectiveness Observed Among Trimethoprim/Sulfamethoxazole Plus Clindamycin or Caspofungin, and Trimethoprim/Sulfamethoxazole Monotherapy in HIV-Infected Patients with Moderate to Severe Pneumocystis Pneumonia: Results of an Observational Multicenter Cohort Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 543-557.	1.8	6
2	Single-Cell Sequencing Facilitates Elucidation of HIV Immunopathogenesis: A Review of Current Literature. <i>Frontiers in Immunology</i> , 2022, 13, 828860.	2.2	5
3	A Dual Role of Heme Oxygenase-1 in Tuberculosis. <i>Frontiers in Immunology</i> , 2022, 13, 842858.	2.2	17
4	HIV-associated talaromycosis: Does timing of antiretroviral therapy matter?. <i>Journal of Infection</i> , 2022, 84, 410-417.	1.7	10
5	Therapeutic lumbar puncture and lumbar drainage: which is more effective for the management of intracranial hypertension in HIV patients with cryptococcal meningitis? Results of a prospective non-randomized interventional study in China. <i>Current Medical Research and Opinion</i> , 2022, 38, 803-810.	0.9	2
6	Pretreatment drug resistance in people living with HIV: A large retrospective cohort study in Chongqing, China. <i>HIV Medicine</i> , 2022, 23, 95-105.	1.0	7
7	Multicentre derivation and validation of a prognostic scoring system for mortality assessment in HIV-infected patients with talaromycosis. <i>Mycoses</i> , 2021, 64, 203-211.	1.8	5
8	Timing of antiretroviral therapy for HIV-infected patients with cytomegalovirus retinitis: study protocol of a multi-center prospective randomized controlled trial. <i>Trials</i> , 2021, 22, 218.	0.7	1
9	The development and validation of a diagnostic scoring system to differentiate pulmonary tuberculosis from non-tuberculosis pulmonary infections in HIV-infected patients with severe immune suppression. <i>BMC Infectious Diseases</i> , 2021, 21, 863.	1.3	0
10	P-Selectin Glycoprotein Ligand 1: A Potential HIV-1 Therapeutic Target. <i>Frontiers in Immunology</i> , 2021, 12, 710121.	2.2	6
11	Establishment of a novel scoring model for mortality risk prediction in HIV-infected patients with cryptococcal meningitis. <i>BMC Infectious Diseases</i> , 2021, 21, 786.	1.3	8
12	The Effect of Early vs. Deferred Antiretroviral Therapy Initiation in HIV-Infected Patients With Cryptococcal Meningitis: A Multicenter Prospective Randomized Controlled Analysis in China. <i>Frontiers in Medicine</i> , 2021, 8, 779181.	1.2	3
13	Alcohol Use and Abuse Conspires With HIV Infection to Aggravate Intestinal Dysbiosis and Increase Microbial Translocation in People Living With HIV: A Review. <i>Frontiers in Immunology</i> , 2021, 12, 741658.	2.2	4
14	The Optimal Timing of Antiretroviral Therapy Initiation in HIV-Infected Patients with Cryptococcal Meningitis: A Multicenter Prospective Randomized Controlled Trial. <i>Acta Medica Okayama</i> , 2021, 75, 109-113.	0.1	0
15	No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labelled Prospective Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 1071.	1.6	46
16	Asymptomatic cryptococcal antigenemia in HIV-infected patients: a review of recent studies. <i>Chinese Medical Journal</i> , 2020, 133, 2859-2866.	0.9	0
17	Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol. <i>Chinese Medical Journal</i> , 2020, 133, 1132-1134.	0.9	42
18	Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial. <i>Chinese Medical Journal</i> , 2020, 133, 1080-1086.	0.9	88

#	ARTICLE	IF	CITATIONS
19	Six weeks into the 2019 coronavirus disease outbreak: it is time to consider strategies to impede the emergence of new zoonotic infections. Chinese Medical Journal, 2020, 133, 1118-1120.	0.9	15
20	Timing of antiretroviral therapy for HIV-infected patients with moderate to severe Pneumocystis pneumonia: study protocol for a multi-centre prospective randomised controlled trial. Trials, 2020, 21, 551.	0.7	2
21	JC Polyomavirus, progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome: a review. AIDS Research and Therapy, 2020, 17, 37.	0.7	19
22	Independent Risk Factors for Deaths due to AIDS in Chongqing, China: Does Age Matter?. Frontiers in Medicine, 2020, 7, 586390.	1.2	5
23	Predictive factors of progression to severe COVID-19. Open Medicine (Poland), 2020, 15, 805-814.	0.6	4
24	Comparative Effectiveness and Safety of Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients with Mild to Moderate Novel Coronavirus Pneumonia: Results of a Randomized, Open-Labeled Prospective Study. SSRN Electronic Journal, 0, , .	0.4	7
25	Efficacy and Safety of Voriconazole Versus AmphotericinÂB Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in China. Infectious Diseases and Therapy, 0, , .	1.8	1